Clinical Trials
28 trialsComparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment
Peking University Cancer Hospital & Institute
GISTAR-1
Ningbo Newbay Technology Development Co., Ltd
Regbone
Institute of Mother and Child, Warsaw, Poland
EREMISS
Centre Oscar Lambret
REGO-SARC
Centre Oscar Lambret
REGOSTA
Centre Leon Berard
Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body
Children's Oncology Group
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
M.D. Anderson Cancer Center
REGO-INTER-EWI
Gustave Roussy, Cancer Campus, Grand Paris
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
Sarcoma Alliance for Research through Collaboration
REGOBONE
UNICANCER
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
University of Miami
FaR-RMS
University of Birmingham
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
Bayer
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Sarcoma Alliance for Research through Collaboration
ALT GIST
Australasian Gastro-Intestinal Trials Group
REFIT-MSS
Translational Research in Oncology
REGISTRI
Grupo Espanol de Investigacion en Sarcomas
REGOMUNE
Institut Bergonié
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
Blueprint Medicines Corporation
RESOUND
Istituto Clinico Humanitas
Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
Northwestern University
SURE
Dana-Farber Cancer Institute
GRID
Bayer
Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Dana-Farber Cancer Institute
Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs
Asan Medical Center
Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation
Chang Gung Memorial Hospital
REGORA
Erasmus Medical Center